Novel point mutation (W184R) in neonatal type 2 Gaucher disease

Gaucher disease is the most prevalent inherited sphingolipidosis and results from deficient glucocerebrosidase activity. Three clinical forms of Gaucher disease have been described: type 1, or non-neuronopathic; type 2, or acute neuronopathic; and type 3, or subacute neuronopathic. We have identifie...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pediatric and developmental pathology 2000-03, Vol.3 (2), p.180-183
Hauptverfasser: Choy, F Y, Wong, K, Vallance, H D, Baldwin, V
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 183
container_issue 2
container_start_page 180
container_title Pediatric and developmental pathology
container_volume 3
creator Choy, F Y
Wong, K
Vallance, H D
Baldwin, V
description Gaucher disease is the most prevalent inherited sphingolipidosis and results from deficient glucocerebrosidase activity. Three clinical forms of Gaucher disease have been described: type 1, or non-neuronopathic; type 2, or acute neuronopathic; and type 3, or subacute neuronopathic. We have identified a novel mutation in a patient of Russian-British descent who died of type 2 Gaucher disease a few hours after birth. A heterozygous T --> C transition mutation in exon 6, cDNA nucleotide position 667, results in the substitution of tryptophan by arginine at amino acid residue 184 (W184R) of glucocerebrosidase. This mutation creates a new cleavage site for the restriction endonuclease Hinf1. We developed a method that utilizes Hinf1 restriction endonuclease analysis to confirm the presence of the mutation and test family members. The second mutation identified in the other glucocerebrosidase allele of the patient is mutation L444P, a severe mutation frequent in type 2 and 3 Gaucher disease. Since the patient died very shortly after birth, we postulate that the W184R/L444P genotype may result in little or no detectable glucocerebrosidase activity and thus a poor prognosis.
doi_str_mv 10.1007/s100249910018
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_70908605</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70908605</sourcerecordid><originalsourceid>FETCH-LOGICAL-p122t-7858f4295909f84c901570609525a4af26b6a36bb41809304d96d32d69a15f5c3</originalsourceid><addsrcrecordid>eNo1j01LxDAYhHNQ3HX16FVyEj1U33wnJ5FFV2FREMVjedumGOmXTSrsv7fgepmB4WGYIeSMwTUDMDdxVi6dm43ZA7Jk4ESmuNYLchzj15wao-GILBho40DYJbl97n98Q4c-dIm2U8IU-o5efjArX69o6Gjn-w4TNjTtBk853eBUfvqRViF6jP6EHNbYRH-69xV5f7h_Wz9m25fN0_pumw2M85QZq2wtuVMOXG1l6YApAxqc4gol1lwXGoUuCsnsPBpk5XQleKUdMlWrUqzIxV_vMPbfk48pb0MsfdPgPHCKuQEHVoOawfM9OBWtr_JhDC2Ou_z_svgFQz9SjQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70908605</pqid></control><display><type>article</type><title>Novel point mutation (W184R) in neonatal type 2 Gaucher disease</title><source>MEDLINE</source><source>SAGE Complete A-Z List</source><source>Alma/SFX Local Collection</source><creator>Choy, F Y ; Wong, K ; Vallance, H D ; Baldwin, V</creator><creatorcontrib>Choy, F Y ; Wong, K ; Vallance, H D ; Baldwin, V</creatorcontrib><description>Gaucher disease is the most prevalent inherited sphingolipidosis and results from deficient glucocerebrosidase activity. Three clinical forms of Gaucher disease have been described: type 1, or non-neuronopathic; type 2, or acute neuronopathic; and type 3, or subacute neuronopathic. We have identified a novel mutation in a patient of Russian-British descent who died of type 2 Gaucher disease a few hours after birth. A heterozygous T --&gt; C transition mutation in exon 6, cDNA nucleotide position 667, results in the substitution of tryptophan by arginine at amino acid residue 184 (W184R) of glucocerebrosidase. This mutation creates a new cleavage site for the restriction endonuclease Hinf1. We developed a method that utilizes Hinf1 restriction endonuclease analysis to confirm the presence of the mutation and test family members. The second mutation identified in the other glucocerebrosidase allele of the patient is mutation L444P, a severe mutation frequent in type 2 and 3 Gaucher disease. Since the patient died very shortly after birth, we postulate that the W184R/L444P genotype may result in little or no detectable glucocerebrosidase activity and thus a poor prognosis.</description><identifier>ISSN: 1093-5266</identifier><identifier>DOI: 10.1007/s100249910018</identifier><identifier>PMID: 10679038</identifier><language>eng</language><publisher>United States</publisher><subject>Base Sequence ; DNA - analysis ; DNA Primers - chemistry ; DNA Restriction Enzymes - metabolism ; Fatal Outcome ; Gaucher Disease - enzymology ; Gaucher Disease - genetics ; Gaucher Disease - pathology ; Glucosylceramidase - genetics ; Humans ; Infant, Newborn ; Molecular Sequence Data ; Point Mutation ; Polymerase Chain Reaction ; Polymorphism, Restriction Fragment Length ; Restriction Mapping - methods</subject><ispartof>Pediatric and developmental pathology, 2000-03, Vol.3 (2), p.180-183</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10679038$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Choy, F Y</creatorcontrib><creatorcontrib>Wong, K</creatorcontrib><creatorcontrib>Vallance, H D</creatorcontrib><creatorcontrib>Baldwin, V</creatorcontrib><title>Novel point mutation (W184R) in neonatal type 2 Gaucher disease</title><title>Pediatric and developmental pathology</title><addtitle>Pediatr Dev Pathol</addtitle><description>Gaucher disease is the most prevalent inherited sphingolipidosis and results from deficient glucocerebrosidase activity. Three clinical forms of Gaucher disease have been described: type 1, or non-neuronopathic; type 2, or acute neuronopathic; and type 3, or subacute neuronopathic. We have identified a novel mutation in a patient of Russian-British descent who died of type 2 Gaucher disease a few hours after birth. A heterozygous T --&gt; C transition mutation in exon 6, cDNA nucleotide position 667, results in the substitution of tryptophan by arginine at amino acid residue 184 (W184R) of glucocerebrosidase. This mutation creates a new cleavage site for the restriction endonuclease Hinf1. We developed a method that utilizes Hinf1 restriction endonuclease analysis to confirm the presence of the mutation and test family members. The second mutation identified in the other glucocerebrosidase allele of the patient is mutation L444P, a severe mutation frequent in type 2 and 3 Gaucher disease. Since the patient died very shortly after birth, we postulate that the W184R/L444P genotype may result in little or no detectable glucocerebrosidase activity and thus a poor prognosis.</description><subject>Base Sequence</subject><subject>DNA - analysis</subject><subject>DNA Primers - chemistry</subject><subject>DNA Restriction Enzymes - metabolism</subject><subject>Fatal Outcome</subject><subject>Gaucher Disease - enzymology</subject><subject>Gaucher Disease - genetics</subject><subject>Gaucher Disease - pathology</subject><subject>Glucosylceramidase - genetics</subject><subject>Humans</subject><subject>Infant, Newborn</subject><subject>Molecular Sequence Data</subject><subject>Point Mutation</subject><subject>Polymerase Chain Reaction</subject><subject>Polymorphism, Restriction Fragment Length</subject><subject>Restriction Mapping - methods</subject><issn>1093-5266</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1j01LxDAYhHNQ3HX16FVyEj1U33wnJ5FFV2FREMVjedumGOmXTSrsv7fgepmB4WGYIeSMwTUDMDdxVi6dm43ZA7Jk4ESmuNYLchzj15wao-GILBho40DYJbl97n98Q4c-dIm2U8IU-o5efjArX69o6Gjn-w4TNjTtBk853eBUfvqRViF6jP6EHNbYRH-69xV5f7h_Wz9m25fN0_pumw2M85QZq2wtuVMOXG1l6YApAxqc4gol1lwXGoUuCsnsPBpk5XQleKUdMlWrUqzIxV_vMPbfk48pb0MsfdPgPHCKuQEHVoOawfM9OBWtr_JhDC2Ou_z_svgFQz9SjQ</recordid><startdate>200003</startdate><enddate>200003</enddate><creator>Choy, F Y</creator><creator>Wong, K</creator><creator>Vallance, H D</creator><creator>Baldwin, V</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>200003</creationdate><title>Novel point mutation (W184R) in neonatal type 2 Gaucher disease</title><author>Choy, F Y ; Wong, K ; Vallance, H D ; Baldwin, V</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p122t-7858f4295909f84c901570609525a4af26b6a36bb41809304d96d32d69a15f5c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Base Sequence</topic><topic>DNA - analysis</topic><topic>DNA Primers - chemistry</topic><topic>DNA Restriction Enzymes - metabolism</topic><topic>Fatal Outcome</topic><topic>Gaucher Disease - enzymology</topic><topic>Gaucher Disease - genetics</topic><topic>Gaucher Disease - pathology</topic><topic>Glucosylceramidase - genetics</topic><topic>Humans</topic><topic>Infant, Newborn</topic><topic>Molecular Sequence Data</topic><topic>Point Mutation</topic><topic>Polymerase Chain Reaction</topic><topic>Polymorphism, Restriction Fragment Length</topic><topic>Restriction Mapping - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Choy, F Y</creatorcontrib><creatorcontrib>Wong, K</creatorcontrib><creatorcontrib>Vallance, H D</creatorcontrib><creatorcontrib>Baldwin, V</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatric and developmental pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Choy, F Y</au><au>Wong, K</au><au>Vallance, H D</au><au>Baldwin, V</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Novel point mutation (W184R) in neonatal type 2 Gaucher disease</atitle><jtitle>Pediatric and developmental pathology</jtitle><addtitle>Pediatr Dev Pathol</addtitle><date>2000-03</date><risdate>2000</risdate><volume>3</volume><issue>2</issue><spage>180</spage><epage>183</epage><pages>180-183</pages><issn>1093-5266</issn><abstract>Gaucher disease is the most prevalent inherited sphingolipidosis and results from deficient glucocerebrosidase activity. Three clinical forms of Gaucher disease have been described: type 1, or non-neuronopathic; type 2, or acute neuronopathic; and type 3, or subacute neuronopathic. We have identified a novel mutation in a patient of Russian-British descent who died of type 2 Gaucher disease a few hours after birth. A heterozygous T --&gt; C transition mutation in exon 6, cDNA nucleotide position 667, results in the substitution of tryptophan by arginine at amino acid residue 184 (W184R) of glucocerebrosidase. This mutation creates a new cleavage site for the restriction endonuclease Hinf1. We developed a method that utilizes Hinf1 restriction endonuclease analysis to confirm the presence of the mutation and test family members. The second mutation identified in the other glucocerebrosidase allele of the patient is mutation L444P, a severe mutation frequent in type 2 and 3 Gaucher disease. Since the patient died very shortly after birth, we postulate that the W184R/L444P genotype may result in little or no detectable glucocerebrosidase activity and thus a poor prognosis.</abstract><cop>United States</cop><pmid>10679038</pmid><doi>10.1007/s100249910018</doi><tpages>4</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1093-5266
ispartof Pediatric and developmental pathology, 2000-03, Vol.3 (2), p.180-183
issn 1093-5266
language eng
recordid cdi_proquest_miscellaneous_70908605
source MEDLINE; SAGE Complete A-Z List; Alma/SFX Local Collection
subjects Base Sequence
DNA - analysis
DNA Primers - chemistry
DNA Restriction Enzymes - metabolism
Fatal Outcome
Gaucher Disease - enzymology
Gaucher Disease - genetics
Gaucher Disease - pathology
Glucosylceramidase - genetics
Humans
Infant, Newborn
Molecular Sequence Data
Point Mutation
Polymerase Chain Reaction
Polymorphism, Restriction Fragment Length
Restriction Mapping - methods
title Novel point mutation (W184R) in neonatal type 2 Gaucher disease
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T19%3A44%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Novel%20point%20mutation%20(W184R)%20in%20neonatal%20type%202%20Gaucher%20disease&rft.jtitle=Pediatric%20and%20developmental%20pathology&rft.au=Choy,%20F%20Y&rft.date=2000-03&rft.volume=3&rft.issue=2&rft.spage=180&rft.epage=183&rft.pages=180-183&rft.issn=1093-5266&rft_id=info:doi/10.1007/s100249910018&rft_dat=%3Cproquest_pubme%3E70908605%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70908605&rft_id=info:pmid/10679038&rfr_iscdi=true